Can Long-Acting HIV Therapy Solve Adherence Struggles?

Daily oral antiretroviral therapy remains the standard of care for HIV management worldwide. However, many individuals struggle with pill adherence due to stigma, pill fatigue, or complex socioeconomic factors. Consequently, clinicians urgently need alternative therapeutic strategies to prevent viral rebound. Recent clinical evidence demonstrates that long-acting HIV therapy provides a robust solution for patients who face major adherence barriers.

Evaluating Long-Acting HIV Therapy in Clinical Practice

The phase 3b IMPALA trial evaluated injectable cabotegravir and rilpivirine administered every two months. Specifically, investigators compared this injectable dual regimen against daily oral dolutegravir-based therapy across African centers. The study enrolled adults who had experienced previous adherence challenges or high viral loads. Before randomization, all participants achieved viral suppression using oral regimens.

Furthermore, the trial assessed viral suppression rates at 48 weeks as the primary endpoint. At 48 weeks, 91% of participants receiving injectables maintained viral suppression. Meanwhile, 89.2% of participants in the daily oral group maintained suppression. Therefore, the long-acting injectable regimen met the criteria for non-inferiority compared to daily oral therapy. In addition, confirmed virologic failure remained very low in both study arms.

Key Clinical Benefits and Patient Preferences

Patient satisfaction plays a decisive role in long-term HIV management. Notably, over 93% of participants receiving injections preferred the bimonthly shots over daily oral tablets. This high preference rate highlights the psychosocial relief that patients experience when free from daily pill reminders.

Moreover, health workers directly administer and monitor these intramuscular injections. As a result, healthcare teams can identify missed doses immediately. Conversely, missed oral doses often go unnoticed until clinical failure occurs. Nevertheless, providers must manage logistical requirements, including regular clinic visits and cold-chain storage. Injection-site discomfort also represents a frequent adverse event, though symptoms remain predominantly mild.

Implications for Indian Healthcare Providers

In India, daily dolutegravir forms the backbone of national first-line antiretroviral regimens. However, Indian physicians frequently encounter patients who struggle with chronic adherence due to work-related travel and societal stigma. Thus, long-acting options could dramatically improve clinical outcomes in selected high-risk cohorts.

Furthermore, as regulatory agencies evaluate long-acting formulations, Indian clinicians should understand patient selection criteria. Specifically, patients must achieve viral suppression before switching to cabotegravir and rilpivirine. Additionally, clinicians must ensure strict adherence to the bimonthly injection calendar to prevent drug resistance.

Frequently Asked Questions

Q1: What drugs constitute this long-acting injectable regimen?

The regimen combines cabotegravir, an integrase strand transfer inhibitor, and rilpivirine, a non-nucleoside reverse transcriptase inhibitor. Clinicians administer these drugs as separate intramuscular injections every two months.

Q2: Can patients with unsuppressed viral loads switch immediately to injections?

In standard practice, patients must first achieve viral suppression on an oral regimen before switching. This trial required viral loads below 200 copies/mL before participants transitioned to the long-acting injectable therapy.

Q3: What are the main challenges associated with injectable HIV therapy?

The primary challenges include mild injection-site pain, mandatory bimonthly clinic appointments, and specialized cold-chain storage. Furthermore, missing an injection window risks subtherapeutic drug levels and potential viral resistance.

References

1. Cresswell FV et al. Long-Acting HIV Therapy in African Adults with Adherence Challenges. N Engl J Med. 2026 Oct 15. doi: 10.1056/NEJMoa2518753. PMID: 42874104.
2. Rana AI et al. Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges. N Engl J Med. 2026; doi: 10.1056/NEJMoa2508228.
3. World Health Organization. Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring. Geneva: World Health Organization; 2021.